Development of cannabinoid receptor (CB 2 R) ligands for application in PET studies - where to attach the radiolabel?
© Günther et al; licensee Chemistry Central Ltd. 2014
Published: 11 March 2014
The cannabinoid receptors type 2 (CB2R) are involved in many physiological processes but their expression level in healthy and diseased brain has not been unravelled. With positron emission tomography (PET) it is possible to monitor quantitatively very low amounts of compounds labelled with positron emitting isotopes like 18F in living organisms at high spatial resolution. For application in clinical research, such radiotracers have to show high selectivity and affinity to the target protein.
- Rühl T, Deuther-Conrad W, Fischer S, Günther R, Hennig L, Krautscheid L, Brust P: Cannabinoid Receptor Type 2 (CB2)-Selective N-Aryl-Oxadiazolyl-Propionamides: Synthesis, Radiolabelling, Molecular Modelling and Biological Evaluation. Org Med Chem Lett. 2012, 2: 32-10.1186/2191-2858-2-32.View ArticleGoogle Scholar
- Günther R, Brust P: Synergistic approach of structure- based and ligand-based drug design for the development of selective cannabinoid receptor ligands. J Cheminform. 2012, 4 (Suppl 1): P11-10.1186/1758-2946-4-S1-O11.View ArticleGoogle Scholar
- Gerebtzoff G, Seelig A: In Silico Prediction of Blood-Brain Barrier Permeation Using the Calculated Molecular Cross-Sectional Area as Main Parameter. J Chem Inf Model. 2006, 6: 2638-2650.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.